Findings on sphingolipid biosynthesis may lead to new treatments for metabolic diseases

Research led by SUNY Downstate Medical Center shows that blockage of sphingolipid de novo synthesis pathway (through knockout Serine Palmitoyltransferase, the key enzyme in the pathway) impairs hepatocyte polarity, attenuates liver regeneration after hepatectomy, and promotes tumorigenesis. This study may provide a guide for the development of serine palmitoyltransferase inhibitors, which have a potential for the treatment of metabolic diseases such as diabetes.
Go to Source